Daily Bio News Summary — 2026-08-11: Biotech IPO Window Reopens as Vaderis, Epicrispr, and Infinimmune Close Major Rounds; FDA Rejects ITM Radiopharma Over Manufacturing

Today’s Harvest at a Glance

Thirty-eight articles across eight sources today (2026-08-11), with the lion’s share from PR Newswire FDA (9), Endpoints News (8), Fierce Biotech (6), and STAT News (5). Clinical regulatory stories account for 14 of the 38, followed by therapeutics development (15) and business/strategy (8). Notably absent from today’s batch: AI-bio platform announcements, major public-market IPO filings (though the venture market is clearly active), and mega-cap M&A.

Venture Capital: Three Major Rounds Signal Strong Biotech Appetite

The dominant theme today is venture capital activity in rare disease and antibody therapeutics. Three rounds closed in the $75M–$152M range, all targeting early-stage companies with novel platforms.

Vaderis Therapeutics (Basel, Switzerland) closed a $152M Series B to advance its Phase 3 program in Hereditary Hemorrhagic Telangiectasia (HHT) and a Phase 2 program in broader vascular malformations (Fierce Biotech, 2026-08-11). The company holds FDA Fast Track designation and is one of the few clinical-stage biotechs focused exclusively on vascular malformations caused by rare genetic disorders.

Epicrispr Biotechnologies (Cambridge, MA) raised $90M to advance its epigenetic editing platform, led by EPI-321 for facioscapulohumeral muscular dystrophy (FSHD) in Phase 1/2 (Fierce Biotech, 2026-08-11). The company’s approach targets the genetic root cause of FSHD via DUX4 silencing — a mechanism distinct from gene replacement therapies. Additional preclinical programs address alpha-1 antitrypsin deficiency and familial hypercholesterolemia.

Infinimmune (South San Francisco) raised a $75M Series A backed by Regeneron Ventures, ARCH Venture Partners, and GV to develop therapeutics from rare human antibodies for autoimmune diseases (Fierce Biotech, 2026-08-11). The company’s platform surfaces and engineers complete human antibodies — a differentiated approach from conventional antibody discovery. The Regeneron backing is notable given Regeneron’s own antibody expertise (VelocImmune platform).

A related Endpoints roundup piece (2026-08-11) ties the Infinimmune raise to a broader trend: Eli Lilly paid $2B upfront for vaccine biotechs, suggesting large pharma is willing to pay premium valuations for differentiated antibody and vaccine platforms.

FDA Activity: Rejections and Clearances Shape the Regulatory Landscape

Two FDA rejections dominated regulatory coverage today.

ITM Isotope Technologies (Endpoints News, BioSpace, Fierce Pharma — canonical: Endpoints, 2026-08-11) received a Complete Response Letter (CRL) for its radiopharma therapy, with manufacturing quality issues cited as the reason. This is the second major radiopharma setback in recent weeks and underscores the FDA’s heightened scrutiny of manufacturing standards for complex drug products. Three sources covered this story, reflecting its significance to the radiopharma sector.

Scholar Rock (Endpoints News, 2026-08-11) dropped a Novo Nordisk manufacturing site from its SMA drug application after FDA flagged violations at the Novo plant. The company is reworking its regulatory filing, but the delay adds uncertainty to an already competitive SMA market.

On the clearance side:

• Graviton BioScience received FDA IND clearance for GV101 for Friedreich’s Ataxia (PR Newswire, 2026-08-11).
• FastWave Medical gained FDA IDE approval to begin a pivotal trial of its Artero peripheral IVL system for calcified peripheral artery disease (PR Newswire, 2026-08-11).
• Spineart secured FDA approval of the BAGUERA C cervical disc (PR Newswire, 2026-08-11).
• EIT Pharma received FDA acceptance of its NDA for lonafarnib for chronic hepatitis delta (PR Newswire, 2026-08-11).
• Lupin gained FDA approval for sodium zirconium cyclosilicate oral suspension (PR Newswire, 2026-08-10).

Manufacturing: BMS Commits $2.3B to Houston

Bristol Myers Squibb (Endpoints News, Fierce Pharma — canonical: Endpoints, 2026-08-11) detailed a $2.3B manufacturing campus in Houston, one of the largest single-site biopharma manufacturing investments in recent years. The move signals BMS’s commitment to US-based production capacity amid ongoing supply chain concerns and tariff pressures (Reuters, 2026-08-11, on global drugmakers investing to boost US presence).

M&A: Jazz Expands in Epilepsy, Sentynl Buys Mereo Rare Lung Disease Asset

Jazz Pharmaceuticals (MedCity News, 2026-08-01) is expanding again in epilepsy with the $820M acquisition of Actio Biosciences, gaining access to Actio’s KCNT1 inhibitor for genetic epilepsy and TRPV4 inhibitor for Charcot-Marie-Tooth disease. Actio’s genetics-driven precision medicine approach aligns with Jazz’s neurology-focused portfolio.

Sentynl Therapeutics (Fierce Biotech, 2026-08-11) — part of the Zydus group — penned a $475M deal for Mereo BioPharma’s rare lung disease drug, expanding Sentynl’s rare disease footprint beyond its existing Menkes disease franchise.

Notable Single-Source Stories

• Aura Biosciences is restructuring with a 20% headcount reduction and C-suite changes as it refocuses R&D (Fierce Biotech, 2026-08-11). The company (NASDAQ: AURA) is developing targeted oncology therapies for ocular and urologic cancers.
• AbCellera reported that its menopause medicine “sets a new efficacy bar” for hot flashes in Phase 2 data (BioSpace, 2026-08-10). The NK3R-targeting antibody could be a differentiated non-hormonal option.
• Silence Therapeutics caused a stir in rare blood cancer with data that “sets a high bar for competitors” (BioSpace, 2026-08-10).
• Abbott and Google Health are teaming up on an AI-powered health insights app (Fierce Biotech, 2026-08-11) — a consumer-facing play that reflects the growing convergence of medtech and big tech.
• Ying Huang (former Legend Biotech CMO) is launching K2 Bio with a $250M target to license Asian cell therapy assets into Western markets (Endpoints News, 2026-08-11).

What This Batch Is Not Telling Us

Today’s harvest is heavily weighted toward early-stage financing and regulatory actions. Notably absent:

• IPO filings — no new S-1s today, though the venture activity suggests the IPO window remains open for clinical-stage companies.
• Phase 3 data readouts — no topline results today, though Vaderis has Phase 3 HHT data expected in 2027.
• AI-bio platform news — aside from the Abbott-Google partnership, no major AI drug discovery announcements.
• Public market activity — no major stock-moving events for mid- or large-cap biopharma.

Reading Order

For limited-time readers, today’s highest-signal items are:

1. Vaderis $152M Series B — rare disease vascular malformation, Phase 3, FDA Fast Track (Fierce Biotech)
2. ITM radiopharma CRL — manufacturing failures in radiopharma sector, three-source coverage (Endpoints News)
3. BMS $2.3B Houston campus — major US manufacturing investment (Endpoints News)
4. Epicrispr $90M — epigenetic editing for FSHD, Phase 1/2 (Fierce Biotech)
5. Jazz $820M Actio acquisition — epilepsy expansion (MedCity News)

Source Attribution

All articles sourced from BioSpace, Endpoints News, Fierce Biotech, Fierce Pharma, MedCity News, PR Newswire FDA, Reuters Biopharma, and STAT News, published between 2026-08-01 and 2026-08-11. Per-run harvest: 213 parsed → 189 within 30 days → 38 written (after political filter, cross-source dedup, and URL dedup). 13 company JSONs created for new companies profiled in today’s articles.

1. Vaderis Therapeutics $152M Series B — Fierce Biotech, 2026-08-11
2. Epicrispr Biotechnologies $90M — Fierce Biotech, 2026-08-11
3. Infinimmune $75M Series A backed by Regeneron — Fierce Biotech, 2026-08-11
4. ITM Isotope radiopharma CRL — Endpoints News, 2026-08-11
5. Scholar Rock drops Novo manufacturing site — Endpoints News, 2026-08-11
6. BMS $2.3B Houston manufacturing campus — Endpoints News, 2026-08-11
7. Jazz $820M Actio Biosciences acquisition — MedCity News, 2026-08-01
8. Sentynl/Zydus $475M Mereo rare lung disease deal — Fierce Biotech, 2026-08-11
9. Aura Biosciences 20% headcount reduction, C-suite restructure — Fierce Biotech, 2026-08-11
10. Abbott + Google Health AI-powered health insights app — Fierce Biotech, 2026-08-11
11. Graviton BioScience IND clearance for Friedreich’s Ataxia — PR Newswire FDA, 2026-08-11
12. FastWave Medical FDA IDE approval for Artero IVL — PR Newswire FDA, 2026-08-11
13. Spineart FDA approval of BAGUERA C cervical disc — PR Newswire FDA, 2026-08-11
14. EIT Pharma FDA acceptance of lonafarnib NDA — PR Newswire FDA, 2026-08-11
15. Neurolief expands VA contract for depression neuromodulation — PR Newswire FDA, 2026-08-11
16. Zepto Life Technology $8.9M NIAID contract for liquid biopsy — PR Newswire FDA, 2026-08-11
17. Leica Biosystems multiple FDA digital pathology clearances — PR Newswire FDA, 2026-08-11
18. Novo Nordisk Awiqli once-weekly basal insulin now in US — PR Newswire FDA, 2026-08-11
19. Lupin approval of sodium zirconium cyclosilicate — PR Newswire FDA, 2026-08-10
20. Lilly $2B upfront for vaccine biotechs — Endpoints News, 2026-08-11
21. Ying Huang launches K2 Bio with $250M target — Endpoints News, 2026-08-11
22. WuXi AppTec military company designation blocked — Endpoints News, 2026-08-11
23. Hims & Hers CEO on FDA wellness peptides — Endpoints News, 2026-08-11
24. Manufacturing problems in ITM rejection — BioSpace, 2026-08-11
25. AbCellera menopause medicine efficacy — BioSpace, 2026-08-10
26. Silence Therapeutics rare blood cancer data — BioSpace, 2026-08-10
27. Vaderis $152M Series B (duplicate cross-source — kept BioSpace for detail) — BioSpace, 2026-08-10
28. Austria’s biotech innovation fund — BioSpace, 2026-08-10
29. Global drugmakers investing in US presence — Reuters Biopharma, 2026-08-11
30. Levosimendan Phase 3 stumble — Fierce Pharma, 2026-08-10
31. Inizio Engage Connected Insights — Fierce Pharma, 2026-08-09
32. Medicaid GLP-1 Bridge program challenges — STAT News, 2026-08-11
33. North Star IRB nonprofit model — STAT News, 2026-08-11
34. MMR vaccine splitting evidence — STAT News, 2026-08-11
35. States reaching Medicaid enrollees — STAT News, 2026-08-10
36. Ebola preparedness gap — STAT News, 2026-08-10
37. Senate confirms Erica Schwartz as CDC director — Endpoints News, 2026-08-06
38. AI in drug development: evidence vs data — MedCity News, 2026-08-01